Absoludy COVID-19 Neutralizing Antibody
-
· Absoludy COVID-19 Neutralizing Antibody for ABSOL use is based on the principle of Fluorescence immunoassay detecting semi-quantita- tive value of SARS-CoV-2 Virus's neutralizing antibody.
-
· Measuring the level of COVID-19 Neutralizing Antibody is to help check the overall vaccine efficacy, compare efficacy of different vac- cine candidates, monitor longevity of protective immunity and lead to herd immunity.
· Performance
Total Results for COVID-19 NAb Clinical Agreement
Result |
'A' 2019-nCoV Assay |
---|
Positive |
Negative |
Total |
---|
Absoludy COVID-19 NAb |
Positive |
27 |
0 |
27 |
Negative |
0 |
10 |
10 |
Total |
27 |
10 |
37 |
Clinical Sensitivity: 98%
Clinical Specificity: 99%
|
·Procedure
Sample: Serum or Plasma(heparin, K2 -EDTA), 40μL
· Result & Interpretation
The result of two CH. is determined by ABSOL Cut-off Index (COI)
Test result is negative if COI is< 1.0 and positive if COI is ≥1.0 (Negative "<"1.0, Positive ≥1.0)
· Spectification
AMR |
60~300 IU/mL |
Performance |
Sensitivity: 100%, Specificity: 100% |
Test time |
5 min |
Sample type |
Serum and Plasma(Li-heparin or K2-EDTA) |
Sample Volume |
40µL |
Storage |
2~8 °C |
· Spectification
Cartridge |
20ea |
Pretreatment Tube |
20ea |
Disposable tip |
24ea |
Code chip |
1ea |
Package Insert sheet |
1ea |